[Pangyo Bio & Medical] Theragen Bio registers patent for AI-based cancer vaccine design program… “The goal is to realize personalized medicine and develop treatments for incurable cancer!”

Theragen Bio has completed patent registration for the ‘immunogenicity prediction device, immunogenicity prediction method, and computer program of synthetic long peptides’ for its AI-based cancer vaccine development platform DEEPOMICS® NEO.

The patent registered this time is a method of effectively measuring the immunogenicity of synthetic long peptides (SLPs) used in neoantigen vaccines and designing a vaccine that can maximize the immunogenicity of neoantigen candidates selected through genome analysis and experiments. It’s about.

DEEPOMICS® NEO calculates the SLP by quantifying the immunogenicity of the SLP presented by the injection to be injected into the patient, ▲HLA binding ability of the neoantigen ▲T cell recognition ability ▲cleavage prediction information ▲peptide sequence information, etc. to be injected into the patient’s target cells. This is a program that finds the optimal mutation location within the sequence. The company expects that it will be a groundbreaking technology essential for the development of personalized neoantigen vaccines in the future.

Neoantigen candidate selection programs developed so far have only provided the function of predicting neoantigens that induce a patient’s immune response among mutations discovered through genome analysis, and there is no program that predicts the location of mutations that maximize the immunogenicity of the vaccine. didn’t However, therapeutic cancer vaccines contain neoantigen candidate mutations in the form of long peptide sequences, and the immune response varies greatly depending on the location of the mutation in the SLP sequence, so the need for a program to predict the location of the mutation has continued to emerge.

In addition, in order to activate the immune response against mutations in cancer cells, T cells must be stimulated by antigen presenting cells (APC) and dendritic cells, not cancer cells. The development and advancement of algorithms to predict whether a neoantigen binds to the major histocompatibility complex (MHC) MHC class I (MHC I) and class II (MHC II) has enabled various clinical applications of personalized neoantigen cancer vaccines. It is playing an important role in expanding and applying it to carcinoma.

Baek Soon-myeong, Director (CTO) of Theragen Bio, said, “Development of a vaccine design algorithm that maximizes neoantigen immunogenicity will be an important focus of future neoantigen vaccine research. “The cancer vaccine designed using this patent showed superior immune response induction and treatment effects in preclinical models compared to competitors, and is an advanced technology that can be applied to all vaccine designs,” he said. “We are providing customized medicine through steady research and development.” We will achieve our goal of realizing and developing treatments for incurable cancer.”

Theragen Bio is researching and developing a therapeutic neoantigen cancer vaccine that helps activate immune cells by selectively stimulating T cells that recognize tumor mutations. The field of neoantigen cancer vaccines is attracting attention in the development of cancer treatments because it has the feature of applying the concept of personalized treatment in that neoantigens are selected based on mutation information of different tumors for each individual.

Meanwhile, the company has so far completed registration of 2 patents for DEEPOMICS® MARKER, ▲4 patents for DEEPOMICS® NEO, and a total of 6 patents related to the cancer vaccine platform. In the future, we plan to continue research and development on customized treatment targets for each patient and new drug development to develop the genomic big data platform DEEPOMICS® and innovative genome-based solutions.

Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news